Eying Incyte's Opzelura, Leo Pharma shares data for JAK cream in hand eczema

Back in February, Leo Pharma revealed that its JAK-inhibitor cream delgocitinib met its primary and secondary endpoints in a phase 3 trial in chronic hand eczema, putting pressure on Incyte’s approved topical Opzelura. Now, the Danish dermatology specialist is peeling back the layers on those results.